Market open
BioAtla/$BCAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Ticker
$BCAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
65
Website
BioAtla Metrics
BasicAdvanced
$107M
Market cap
-
P/E ratio
-$2.18
EPS
1.05
Beta
-
Dividend rate
Price and volume
Market cap
$107M
Beta
1.05
52-week high
$4.02
52-week low
$1.14
Average daily volume
1.6M
Financial strength
Current ratio
3.808
Quick ratio
3.531
Total debt to equity
5.298
Management effectiveness
Return on assets (TTM)
-55.37%
Return on equity (TTM)
-134.14%
Valuation
Price to book
3.42
Price to tangible book (TTM)
3.42
Price to free cash flow (TTM)
-0.994
Growth
Earnings per share change (TTM)
-17.80%
3-year earnings per share growth (CAGR)
2.60%
What the Analysts think about BioAtla
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioAtla stock.
BioAtla Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioAtla Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioAtla News
AllArticlesVideos
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
Seeking Alpha·1 month ago
BioAtla: Numerous Catalysts Coming In Q4
Seeking Alpha·1 month ago
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioAtla stock?
BioAtla (BCAB) has a market cap of $107M as of November 08, 2024.
What is the P/E ratio for BioAtla stock?
The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of November 08, 2024.
Does BioAtla stock pay dividends?
No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next BioAtla dividend payment date?
BioAtla (BCAB) stock does not pay dividends to its shareholders.
What is the beta indicator for BioAtla?
BioAtla (BCAB) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.